Navigation Links
New Data Suggests Interferon-Free Therapy Around the Corner for HCV Patients
Date:4/19/2012

References

1. Lawitz E, et al, PSI-7977 PROTON and ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3. Abstract presented at the International Liver Congress™ 2012.

2. Gane EJ, et al, ELECTRON: ONCE DAILY PSI-7977 PLUS RBV IN HCV GT1/2/3. Abstract presented at the International Liver Congress™ 2012.

3. Zeuzem S, et al, SVR4 and SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2. Abstract presented at the International Liver Congress™ 2012.

4. Pawlotsky J-M, et al, ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY. Abstract presented at the International Liver Congress™ 2012.

5. Alberti A, et al, ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR. Abstract presented at the International Liver Congress™ 2012.

6. Sulkowski M, et al, POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/-RIBAVIRIN, IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3. Abstract presented at the International Liver Congress™ 2012.

7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Journal of Hepatology 2011 vol. 55 245–264

8. Fried MW, et al, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002 Sep 26;347(13):975-82.

9. Manns MP, et al, Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a r
'/>"/>

SOURCE European Association for the Study of the Liver
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Journal Article Suggests DermaClose® RC Used in Combination With VAC Therapy Can Dramatically Reduce the Need for Skin Grafting of Fasciotomy Wounds for Combat Related Trauma
2. Grifols Study Suggests Repeated Plasmapheresis May Reduce "Bad" LDL Cholesterol Levels While Increasing "Good" HDL Cholesterol Levels in Some Individuals
3. New Research Suggests That Acthar Reduces Proteinuria in Idiopathic Membranous Nephropathy In Part Through Suppression of Anti-PLA2R Antibodies
4. TRiUS Data Suggests That Testim® Significantly Improved Sexual Function in Hypogonadal Men
5. Help Remedies Suggests People TAKE LESS
6. Research Suggests FORTEO® Significantly Increases Bone Strength
7. Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
8. Leading Rehab Facility Urges Patients Not to Stop Taking Antidepressants After New Study Suggests Increased Risk of Heart Attacks and Strokes
9. New Subgroup Analysis of LUX-Lung 1 Trial Suggests Afatinib Increases Progression-Free Survival in Advanced Lung Cancer Patients More Likely to Have EGFR Mutations
10. Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate
11. Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... is evident from the industry players that as a whole ... to the lack of promotional activities to make consumers aware ... acids. Among omega-3 ingredient sources algal oil is expected to ... vegetarian population in India . ... in growth stage of its lifecycle. Omega-3 fatty acids have ...
(Date:9/30/2014)... CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced the initiation of a ... to topotecan in subjects with extensive-stage small cell ... refractory to prior chemotherapy. Aldoxorubicin is CytRx,s modified ... has received Orphan Drug Designation for the treatment ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
Breaking Medicine Technology:Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... HealthCare presented results from a global Phase II study ... detection of cerebral beta-Amyloid plaques, at the 19th World ... of the Phase II study was to investigate the ... clinical diagnosis of probable Alzheimer,s disease and Healthy Volunteers ...
... ADA,s 2009 Convention -- When Shawnae Jebbia won the ... a fairytale career. She appeared at events throughout the world, ... But Shawnae,s world unexpectedly changed when she was diagnosed with ... adventure, she had a difficult time understanding and accepting the ...
Cached Medicine Technology:Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 3Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3
(Date:9/30/2014)... For millions of overweight Americans, regular exercise remains a ... type 2 diabetes. However, a new study suggests ... for others, depending on their genes. "While physical ... as effective for everyone when it comes to preventing ... Ruth Loos, director of the Genetics of Obesity and ...
(Date:9/30/2014)... Missouri (PRWEB) September 30, 2014 The ... that the SLUCare Physician Group, comprised of more than ... on a number of initiatives. With the recent ... network size, strengthening its market footprint to better respond ... Louis area. , SLPA is a physician-led clinically integrated ...
(Date:9/30/2014)... AxoGen, Inc. (NASDAQ: AXGN), a leading ... market, announced the presentation of clinical data for Avance® ... of the Hand (ASSH) 2014 Annual Meeting which took ... The ASSH Best Paper Award was given to ”Functional ... Large Gap Nerve Discontinuities: Outcomes From a National Registry ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 During ... on natural approaches to health including achieving hormonal ... nutrient deficiencies and detoxification. , ... follows: , Date: October 6-9, 2014, Location: Online ... register: http://www2.hotzehwc.com/naturalhealthsummitregistration , Monday, October 6th, ...
(Date:9/30/2014)... Washington, DC (PRWEB) September 30, 2014 ... private insurance exchanges within three years, profoundly impacting health ... pleased to announce its upcoming virtual conference, “Private ... offer a valuable lesson on where private health insurance ... the industry is expected to look like when they ...
Breaking Medicine News(10 mins):Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5Health News:Hotze Health & Wellness Center Announces First Natural Health Summit 2Health News:New Atlantic Information Services Virtual Conference Will Detail Private Exchange Strategies for Health Plans 2
... to face depression, says a study that suggests that such ... substantial illness with significant morbidity for patients and their families ... the health portal WebMd. , ,Lee S. Cohen ... Boston women aged 36 to 45 for up to six ...
... study in the April edition Journal of the American ... boost the number of children// who select a calcium-rich ... the amount of saturated fat consumed from calcium-rich beverages. ... three ethnically diverse elementary schools in Florida. The results ...
... Children who drink juice do not face the risk of ... of the juice in children’s diet and body mass index ... this conclusion. // ,According to foodconsumer.org, he ... mass index for their age and that children aged 12-18 ...
... in Hypertension: Journal of the American Heart Association sleeping ... may increase risks of high blood pressure. // Columbia ... of Physicians and Surgeons conducted the study. ... at Columbia University's Mailman School of Public Health reported ...
... people were being failed by the NHS says a joint ... Commission for Social Care Inspection. // Elder abuse is hurting ... people are subject to patronising and thoughtless attitudes from some ... place to another, their meals are whisked away uneaten for ...
... men who were born with an "incurable" genetic disorder ... infections has been repaired with Gene therapy. // Sixteen ... the once severely ill patients show signs of complete ... that this latest success will lead to further operations ...
Cached Medicine News:Health News:Neglect of the Elderly by the Community 2Health News:Gene Therapy Helps To Cure 'Incurable' Illness 2
... Model V-1000 is a new addition to the ... This high performance pump can achieve an ultimate ... of 64 L/min. Applications For ... concentrators Distillation applications from lab size ...
... deliver critical performance for all vacuum requirements. ... pump performance to suit all applications. The ... checking of proper oil levels at a ... designed to work with all Thermo Savant ...
... The OFP400 Oil-free Vacuum Pump is designed for ... high chemical resistance, quiet running and eliminates oil ... any oil to operate. Less mess, less fuss., ... 4-headed design with chemically resistant solid ETFE and ...
... several different two-stage, oil-sealed, rotary vane vacuum ... applications. Each pump comes complete with a ... and Oil Mist Filter (EMF-10). The GBORK ... ballast to keep the oil clean without ...
Medicine Products: